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Background
Efficacy of diuretic therapy in congestive heart failure
(CHF) can be affected by renal hemodynamics, neurohu-
moral activation, and diuretic-induced changes in renal
function. Physiological strategies that enhance water and
sodium (Na) excretion while maintaining renal function
are a high priority. Arginine vasopressin increases water
reabsorption after binding to the V2 receptor in the col-
lecting duct (CD). In contrast, B-type natriuretic peptide
(B) decreases Na reabsorption via the particulate guanylyl
cyclase linked natriuretic peptide A receptor (NPR-A) also
in the CD. We hypothesized that coadministration of the
V2-receptor antagonist tolvaptan (T) and B would medi-
ate a diuresis and natriuresis without adversely affecting
renal hemodynamics in experimental CHF.
Methods and results
Severe CHF was induced in 3 groups of dogs by tachypac-
ing. On day 11 cardiorenal function was assessed. After
baseline measurements, one group received T alone (0.1
mg/kg IV bolus; n = 6), one received infusion of B (50 ng/
kg/min; n = 6) and one received both drugs (n = 5).
Changes from baseline were compared with 1-ANOVA.
*p < 0.05. Mean arterial pressure increased with T,
decreased with B, and was unchanged with T+B (+5 ± 1 vs
-14 ± 1 vs -1 ± 1 mmHg, *between groups) with renal per-
fusion pressure paralleling changes in mean arterial pres-
sure. Pulmonary capillary wedge pressure was unchanged
with T and decreased with T+B, but more so with B alone
(*B vs T, T+B). Renal blood flow and glomerular filtration
rate (GFR) were preserved in all groups. Increase in urine
flow was greatest with combined V2 antagonism with T
and NPR A activation with B (T, B, and T+B: +0.4 ± 0.1 vs
+0.9 ± 0.4 vs +2.4 ± 0.5 mL/min, *T+B vs T, B). Electrolyte-
free water excretion was higher with T+B compared to T
and B*. T was not natriuretic, whereas B and T+B were (+0
± 0 vs +76 ± 40 vs +28 ± 10 Eq/min,*T vs B, T+B). Distal
fractional Na reabsorption increased with T, but not with
B and T+B*. Decreases in proximal fractional Na reab-
sorption occurred only with B* and T+B*. Plasma renin
activity was unchanged with T, but suppressed with B and
T+B (*T vs B) while aldosterone which was increased with
T and B, was suppressed by T+B (*T vs T+B).
Conclusion
Coadministration of tolvaptan and BNP enhanced urine
flow and electrolyte-free water excretion greater than
either alone demonstrating a novel mechanism for
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aquaresis in CHF by co-targeting of the V2 and NPR-A
receptor in the CD and linked in part to inhibition of
proximal tubular sodium and water reabsorption during
co-administration. Unlike tolvaptan alone, co-adminis-
tration with BNP also induced a natriuresis. Whereas
tolvaptan increased and BNP decreased mean arterial and
renal perfusion pressure, tolvaptan and BNP coadminis-
tration had a neutral effect. Thus, tolvaptan and BNP
coadministration may be an important and novel physio-
logic strategy to counter sodium and water retention in
CHF.Page 2 of 2
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